Welcome to...The UCLA Endocrine Surgical Unit
 

Schedule an Appointment
Endocrine Home
About Us
Our Expert Team
Our Services
First Visit for Patients
Patient Education
Scar Gallery
For Referring Physicians
Distance Surgery Program
International Patients
Insurance Questions
Map-Directions-Parking
Contact Us
Patient Experiences
Endocrine Resources
Site Map

UCLA Health System


Schedule an Appointment


Parathyroid News Feeds

Worldwide News: View Endocrine News | View Parathyroid News


Wed, 02 Sep 2015 20:22:46 GMT
• Amgen files MAA for IV drug for hyperparathyroidism - Seeking Alpha

Amgen files MAA for IV drug for hyperparathyroidism
Seeking Alpha
Etelcalcetide is a novel calcimimetic agent that suppresses the secretion of parathyroid hormone by binding to the calcium-sensing receptor on the parathyroid gland. It is administered intravenously three times per week at end of each dialysis session ...

and more »

Wed, 02 Sep 2015 20:02:00 GMT
• Amgen (AMGN) Submits Etelcalcetide MAA to EMA - StreetInsider.com

Amgen (AMGN) Submits Etelcalcetide MAA to EMA
StreetInsider.com
Etelcalcetide is a novel calcimimetic agent that suppresses the secretion of parathyroid hormone and is in clinical development for the treatment of SHPT in patients with CKD on hemodialysis. Etelcalcetide is administered intravenously three times per ...

and more »

Sat, 29 Aug 2015 20:02:26 GMT
• New Parathyroid Disease Drug Seeks FDA Approval - Pharmacy Times

New Parathyroid Disease Drug Seeks FDA Approval
Pharmacy Times
New Parathyroid Disease Drug Seeks FDA Approval. Krystle Vermes. Published Online: Saturday, August 29, 2015. Follow Pharmacy_Times: Amgen is seeking FDA approval for etelcalcetide (AMG 461), the first calcimimetic agent administered intravenously ...


Thu, 27 Aug 2015 06:30:42 GMT
• Amgen seeks US FDA approval for etelcalcetide to treat SHPT in patients with ... - pharmabiz.com

Amgen seeks US FDA approval for etelcalcetide to treat SHPT in patients with ...
pharmabiz.com
Etelcalcetide is a novel calcimimetic agent that suppresses the secretion of parathyroid hormone and is in clinical development for the treatment of SHPT in patients with CKD on hemodialysis. Etelcalcetide is administered intravenously three times per ...

and more »

Wed, 26 Aug 2015 21:54:42 GMT
• ?Amgen files for FDA approval for drug to treat dialysis patients - L.A. Biz

L.A. Biz

?Amgen files for FDA approval for drug to treat dialysis patients
L.A. Biz
It suppresses the secretion of parathyroid hormone, which controls the levels of calcium and phosphorous and vitamin D in blood and bone. It acts by binding to and activating the calcium-sensing receptor on the parathyroid gland, thereby causing ...

and more »


Worldwide "Parathyroid" News Courtesy of Google News